Aurinia Pharmaceuticals Inc

Stage 2 · Advancing · week 3

As of Oct 22, 2026, Aurinia Pharmaceuticals is in Stage 2, the uptrend phase, now in week 3 (since Oct 2, 2026). It closed at $17.33, 6.9% below its 52-week high and above its 200-day average, which is rising.

$17.33

+1.82% today

$2.3B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is AUPH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S1 16w

S2 20w

S3 13w

S2 32w

S2 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 7w → S4 10w → S1 8w → S4 17w → S1 16w → S2 20w → S3 13w → S2 3w → S3 3w → S2 32w → S3 9w → S2 16w → S3 4w → S2 1w → S3 3w → S2 3w current

Total tracked: 165 weeks across 16 stage runs.

AUPH among Biotechnology92nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…92	AUPHAurinia Pharmaceuticals Inc	Stage 2 · wk 3	85	+5.7%

vs 52W High

-6.9%

$11.58 lo$18.62 hi

6.9% below 52W high, pullback range

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 3

1w13w26w

Week 3, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

11.1%

200 DMA: $15.60 · rising

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

0.88x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

→

Short-term trend flat

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+5.7%

+12.9%

+7.4%

YTD

+12.9%

+46.4%

Scan Membership

Breakout Watch

Latest: 2025-06-30

11 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 3 · Vol 0.88x

2026-10-21S2

Wk 3 · Vol 0.72x

2026-10-20S2

Wk 3 · Vol 0.66x

2026-10-19S2

Wk 3 · Vol 0.60x

2026-10-16S2

Wk 3 · Vol 0.78x

2026-10-15S2

Wk 2 · Vol 1.09x

2026-10-14S2

Wk 2 · Vol 1.30x

2026-10-13S2

Wk 2 · Vol 1.20x

2026-10-12S2

Wk 2 · Vol 0.68x

2026-10-09S2

Wk 2 · Vol 0.87x

2026-10-08S2

Wk 1 · Vol 0.85x

2026-10-07S2

Wk 1 · Vol 0.69x

Moving averages & range

50 DMA

$16.34

200 DMA

$15.60

52W High

$18.62

52W Low

$11.58

5D Low

$16.49

Resistance levels (recent highs)

20d High

$17.33

60d High

$17.33

120d High

$18.62

250d High

$18.62

Next resistance

+7.4%

to 120d High

P/E (TTM)

7.6

Forward 14.8

Earnings Growth (YoY)

+75.5%

Revenue +18.9%

ROE

+66.1%

Profit margin +100.8%

Dividend Yield

0.00%

P/B 3.7

Aurinia Pharmaceuticals: quick answers

What stage is Aurinia Pharmaceuticals in?

As of Oct 22, 2026, Aurinia Pharmaceuticals (AUPH) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 2, 2026 and is in week 3. What the four stages mean

Is Aurinia Pharmaceuticals in an uptrend?

Yes. Aurinia Pharmaceuticals is in a Stage 2 uptrend. It trades 11.1% above its 200-day average, which is rising.

How far is Aurinia Pharmaceuticals from its 52-week high?

Aurinia Pharmaceuticals closed at $17.33 on Oct 22, 2026, 6.9% below its 52-week high of $18.62. Its 52-week low is $11.58.

How has Aurinia Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Aurinia Pharmaceuticals is up 46.4% over the past year and up 12.9% so far in 2026.

Which sector and industry is Aurinia Pharmaceuticals in?

Aurinia Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.